A practical reference on GHRH analogue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-16 and is reviewed periodically as new material appears.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Procedural aspects in pronouncing death also contribute to delay, so the condemned is usually pronounced dead within 10–20 minutes of starting the drugs. Supporters of the death penalty say that a huge dose of thiopental, which is between 14 and 20 times the anesthetic-induction dose and which has the potential to induce a medical coma lasting 60 hours, could never wear off in only 10–20 minutes.
Cns1 is a oxidoreductase/dehydrogenase. Cns2 is a HDc-family metal-dependent phosphohydrolase. There is a binding interaction between Cns1 and Cns2. Cns3 is a bifunctional protein. It has an N-terminal (9–101 aa) nucleoside/nucleotide kinase (NK) domain and a C-terminal (681-851 aa) HisG-family ATP phosphoribosyltransferase domain. Cns4 is an ABC transporter, specifically of the putative pleiotropic drug resistance (PDR) family. To produce cordycepin:
That evening, the Lebanese Armed Forces (LAF) and UNIFIL withdrew from the Israeli-Lebanese border to the north to a distance of 5 kilometres (3.1 mi; 2.7 nmi) from the border, while the IDF designated the settlements of Metula, Misgav Am and Kfar Giladi as closed military areas. Israeli troops amassed on the border in southern Lebanon, with Israel stating that they were preparing for a limited ground invasion.
Intermediate-level waste (ILW) contains higher amounts of radioactivity compared to low-level waste. It generally requires shielding, but not cooling. Intermediate-level wastes includes resins, chemical sludge and metal nuclear fuel cladding, as well as contaminated materials from reactor decommissioning. It may be solidified in concrete or bitumen or mixed with silica sand and vitrified for disposal. As a general rule, short-lived waste (mainly non-fuel materials from reactors) is buried in shallow repositories, while long-lived waste (from fuel and fuel reprocessing) is deposited in geological repository. Regulations in the United States do not define this category of waste; the term is used in Europe and elsewhere. ILW makes up 6% of all radioactive waste volume in the UK.
=== Toxic exposure === Multiple studies have attempted to study the relationship between toxic exposure and autism, despite limitations related to the measurement of toxic exposure the methods for which were often indirect and cross-sectional. Systematic reviews have been conducted for numerous toxins including air pollution, thimerosal, inorganic mercury, and levels of heavy metals in hair, nails, and bodily fluids. Environmental exposure to inorganic mercury may be associated with higher autism risk, with high levels of mercury in the body being a valid disease-causing agent for autism. Significant evidence has not been found of an association between autism and the concentration of copper, cadmium, selenium, and chromium in the hair, nails, and bodily fluids. Levels of lead were found to be significantly higher in individuals with autism. The precision and consistency of results were not maintained across studies and were influenced by an outlier study. The atypical eating behaviors of autistic children, along with habitual mouthing and pica, make it hard to determine whether increased lead levels are a cause or a consequence of autism.
Sources: en.wikipedia.org
In response, the Greenlandic prime minister Jens-Frederik Nielsen stated that Greenland had no wish to become part of the US. Trump proceeded to threaten him and denied he knew Nielsen. Trump officials again threatened that the American president could take action against Greenland within weeks.
Typhoidal Salmonellae induce their own phagocytosis by host macrophages in vivo and inhibit digestion by lysosomal action, thereby using macrophages for their own replication and causing macrophage apoptosis. Macrophages are capable of engulfing and digesting many bacteria during their life. They can die eventually due to factors including pathogenic cytotoxicity, oxidative stress, and phagocytosis-induced apoptosis. Phagocytosis-induced apoptosis results from the powerful apoptotic stimulus of consuming bacteria and is observed in (at least) macrophages and neutrophils.
Ptaquiloside can pass into the milk produced by bracken-fed cows and sheep. In 1996, Alonso-Amelot, Smith and co-workers found that ptaquiloside was excreted in milk at a concentration of 8.6 ± 1.2% of the amount ingested by a cow from bracken, and was linearly dose-dependent. On the basis of their experiments and the assumption that a person drinks 0.5 litres of milk daily, they estimated that this person might ingest about 10 mg of ptaquiloside per day, although only some of that amount will be absorbed. Ptaquiloside can also leach from the bracken leaves into water and soil. Numerous studies have reported the presence of ptaquiloside in the underground/surface water, and soil near bracken vegetation. The degradation speed of ptaquiloside in the soil is affected by the acidity, clay content, carbon content, temperature and presumably microbioactivity. Acidic condition (pH<4) and high temperature (at least 25 °C) facilitate ptaquiloside degradation, while the half-life of ptaquiloside in less acidic sandy soil is reported to be between 150 and 180 hours.
=== Legal status === The US Food and Drug Administration (FDA) approved tranexamic acid oral tablets (brand name Lysteda) for the treatment of heavy menstrual bleeding in November 2009. In March 2011, the status of tranexamic acid for the treatment of heavy menstrual bleeding was changed in the UK, from POM (Prescription only Medicines) to P (Pharmacy Medicines) and became available over the counter in UK pharmacies under the brand names of Cyklo-F and Femstrual.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.